Department of Otolaryngology Head and Neck Surgery, the First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, China 在知网中查找 在百度中查找 在本站中查找
Department of Otolaryngology Head and Neck Surgery, the First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, China 在知网中查找 在百度中查找 在本站中查找
Department of Otolaryngology Head and Neck Surgery, the First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, China 在知网中查找 在百度中查找 在本站中查找
Department of Otolaryngology Head and Neck Surgery, the First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, China 在知网中查找 在百度中查找 在本站中查找
Department of Otolaryngology Head and Neck Surgery, the First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, China 在知网中查找 在百度中查找 在本站中查找
Department of Otolaryngology Head and Neck Surgery, the First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, China 在知网中查找 在百度中查找 在本站中查找
Objective To study the clinical features, diagnosis, treatments and prognosis of Ewing sarcoma(ES) of the ethmoid sinus in children.Methods The clinical data of one case of ES were analyzed and discussed in combination with relevant literature.Results This patient had primary ethmoid ES. The preoperative diagnosis lacks specific clinical manifestations and imaging features.The final diagnosis was confirmed by histopathology and immunohistochemistry. The patient was treated with surgery combined with chemotherapy and radiotherapy, and no recurrence or metastasis after 8 months of follow-up.Conclusion Ewing sarcoma of the ethmoid sinus is extremely rare, which lacks typical and specific of clinical manifestations.The pathological features are similar to small round cells of other tumors in nasal cavity.Immunomarker CD99+NKX2.2 is recommended for diagnosis of ES. The prognosis of ES of the ethmoid sinus is better with comprehensive treatment.
[1] Negru ME, Sponghini AP, Rondonotti D, et al. Primary Ewing's sarcoma of the sinonasal tract, eroding the ethmoid and sphenoid sinus with intracranial extension:A rare case report[J]. Mol Clin Oncol, 2015, 3(4):807-810.
[2] Lin JK, Liang J. Sinonasal Ewing sarcoma:A case report and literature review[J]. Perm J, 2018, 22:17-86.
[3] Hafezi S, Seethala RR, Stelow EB, et al. Ewing's family of tumors of the sinonasal tract and maxillary bone[J]. Head Neck Pathol, 2011, 5(1):8-16.
[5] Thorn D, Mamot C, Krasniqi F, et al. Multimodality treatment in ewing's sarcoma family tumors of the maxilla and maxillary sinus:review of the literature[J]. Sarcoma, 2016, 2016:3872768.
[6] Amri MF, ABdullah A, Azmi MI, et al. Primary sinonasal Ewing sarcoma:A case report[J]. Malays J Pathol, 2021, 43(2):319-325.
[7] Bridge RS, Rajaram V, Dehner LP, et al. Molecular diagnosis of Ewing sarcoma/primitive neuroectodermal tumor in routinely processed tissue:a comparison of two FISH strategies and RT-PCR in malignant round cell tumors[J]. Mod Pathol, 2006, 19(1):1-8.
[8] Weiss SW, Goldblum JR. Soft tissue tumors of intermediate malignancy of uncertain type. enzinger & weisss soft tissue tumors[M].5th.Philadelphia.PA:Mosby-Elsvier,2008:681-702.
[9] Hafezi S, Seethala RR, Stelow EB, et al. Ewing's family of tumors of the sinonasal tract and maxillary bone[J]. Head Neck Pathol, 2011, 5(1):8-16.
[10] Mccuiston A, Bishop JA. Usefulness of NKX2.2 Immunohistochemistry for distinguishing Ewing sarcoma from other sinonasal small round blue cell tumors[J]. Head Neck Pathol, 2018, 12(1):89-94.
[11] Lin Z, Wu Z, Luo W. A novel treatment for ewing's sarcoma:chimeric antigen receptor-T cell therapy[J]. Front Immunol, 2021, 12:707211.
[12] Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone[J]. N Engl J Med, 2003, 348(8):694-701.
[13] Bosma SE, Van Driel PB, Hogendoorn PC, et al. Introducing fluorescence guided surgery into orthopedic oncology:A systematic review of candidate protein targets for Ewing sarcoma[J]. J Surg Oncol, 2018, 118(6):906-914.
[14] Rijs Z, Jeremiasse B, Shifai N, et al. Introducing fluorescence-guided surgery for pediatric Ewing, osteo-, and rhabdomyosarcomas:A literature review[J]. Biomedicines, 2021, 9(10):1388.
[15] Morales E, Olson M, Iglesias F, et al. Role of immunotherapy in Ewing sarcoma[J]. J Immunother Cancer, 2020, 8(2). 2020,8:e000653.
[16] Sha HH, Wang DD, Yan DL, et al. Chimaeric antigen receptor T-cell therapy for tumour immunotherapy[J]. Biosci Rep, 2017, 37(1).